Anti-obesity drugs like Ozempic stop 10 types of cancer

In Spain, searches related to Muñaro increased by 317.2%.

Arsenal of medicines Diabetes treatment is of growing interest among Spaniards due to its weight loss properties, as evidenced by the significant increase in internet searches, which already reach an average of one hundred thousand searches every month and have grown by more than 300%. But if a few days ago they warned that treatments such as Ozempic or Vegovi could cause blindness, now recent studies guarantee that they can stop up to 13 types of cancer.

Thus, 40% of new cancer diagnoses are related to excess weight, so it is vital that obesity is treated strictly and that the diabetes treatments used to combat this pathology bear fruit. But that’s not all, the study was published this Friday in the journal. JAMA Network is Open found that people with type 2 diabetes who were treated with this class of drugs were less likely to be diagnosed with 10 of 13 obesity-related cancers.

As for the associated types of tumors that could be reduced, the following can be distinguished:
cancer gall bladder, meningioma, pancreas hepatocellular carcinoma, a type of liver cancer, ovarian tumor, colorectal tumor, multiple myeloma, esophageal, endometrial and renal cancer.

In Spain, as well as from various patient associations and scientific societies, health authorities have been forced to consider obesity as a disease that is currently not classified. This has a negative impact on patients and on the treatment of this pathology worldwide. Thus, and among the negative aspects of its non-inclusion, it is worth noting that the treatments for obesity described as Ozempic, Wegoby or Mounjaro must be prescribed by doctors, but must be fully paid for.

A new study involving GLP-1 has found that the treatment is not associated with a reduced risk of postmenopausal breast cancer.

These low risks were also not associated with stomach cancer or the thyroid gland, which in this case can interact with the body’s insulin production, which can negatively affect the thyroid gland and therefore should be monitored regularly.

The advantage of conducting research using these treatments, which are so widely used by patients around the world, is that researchers from Case Western Reserve University School of Medicine and the MetroHealth System were able to analyze more than a decade of medical records from nearly 1.7 million people with type 2 diabetes.

Miracle cure

In the case of Ozempic, originally developed by a Danish company to treat type 2 diabetes. Nordiskwas the drug that awakened the fever for rapid weight loss in Spain. The number of searches by Spanish Internet users related to this drug has increased by 307.7% in the last two years, with an average of 61,948 searches per month. This is why Ozempic positions itself as the most popular treatment in Spain.

However, it was not the first to hit the market. Saxenda, the first drug approved in Spain for weight loss, was available in pharmacies for six years. With an average monthly search volume of 27,420, it is the most consolidated, showing a growth rate of 49.7%. In turn, Wegovy, developed by the same company Ozempic with a more targeted approach to weight loss, accumulates an average of 4926 search queries.

A few weeks ago, Muñaro was presented in Spain, a drug that promises to displace Ozempic, standing out for its superior efficacy, allowing weight loss of up to 22.5% compared to 16% for Ozempic. This drug, which will be available from July 1, 2024, has already been approved European Medicines Agency and has achieved success in countries such as Germany, the UK and the US. According to research by Semrush, the global online search volume for the brand is approaching two million, showing an 83% growth trend over the past year.

In Spain, searches related to Muñaro have increased by 317.2% in recent months, positioning the country as a cruel Ozempic competitor in terms of popularity and interest on the Internet. At the international level, the same trend is observed for all drugs of this type.